Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)
ConclusionsMostALK+ aNSCLC patients with prolonged crizotinib efficacy had paucisymptomatic and oligometastatic disease without BMs. They subsequently benefited from a sequential strategy with other ALK-TKIs.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Brain | Brain Cancers | Cancer | Cancer & Oncology | Neurology | Non-Small Cell Lung Cancer | Smokers | Study